Agenus provides update on balstilimab development

Lexington, mass., oct. 22, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced a strategic decision to withdraw its biologics license application (bla) for balstilimab, its pd-1 inhibitor. the decision to withdraw the bla does not change the development plans for balstilimab combinations.
AGEN Ratings Summary
AGEN Quant Ranking